Table 1 Clinical characteristics of AML patients in a clinical validation cohort.

From: Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer

Characteristics

Total (N = 51)

AIMP2-DX2 negative (N = 29)

AIMP2-DX2 positive (N = 22)

P value

Gender, n (%)

   

0.742

    Male

28 (54.9)

17 (58.6)

11 (50.0)

 

    Female

23 (45.1)

12 (41.4)

11 (50.0)

 

Age, median years (range)

54.3 (20.4–83.8)

50.8 (21.1–72.7)

61.4 (20.4–83.8)

0.213a

FAB classification

   

0.108b

    M0

1 (2.0)

1 (3.4)

0 (0.0)

 

    M1

9 (17.6)

5 (17.2)

4 (13.8)

 

    M2

17 (33.3)

13 (44.8)

4 (13.8)

 

    M3

6 (11.8)

3 (10.3)

3 (10.3)

 

    M4

11 (21.6)

7 (24.1)

4 (13.8)

 

    M4e

2 (3.9)

0 (0.0)

2 (6.9)

 

    M5

2 (3.9)

0 (0.0)

2 (6.9)

 

    M7

1 (2.0)

0 (0.0)

1 (3.4)

 

 Not-specified

2 (3.9)

0 (0.0)

2 (6.9)

 

MRC risk group

   

0.631b

    Low

13 (25.5)

7 (24.1)

6 (20.7)

 

    Intermediate

33 (64.7)

18 (62.1)

15 (51.7)

 

    High

5 (9.8)

4 (13.8)

1 (3.4)

 
  1. FAB classification French–American–British classification, MRC risk group Medical Research Council risk group.
  2. aEstimated by Mann–Whitney U test.
  3. bEstimated by Fisher’s exact test.
Back to article page